文献速递前列腺癌

非转移性去势抵抗性前列腺癌的治疗:聚焦第二代雄激素受体抑制剂

Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-02-08

本文综述了非转移性去势抵抗性前列腺癌(nmCRPC)的早期治疗依据,重点讨论阿帕他胺、恩扎卢胺和达罗他胺三种第二代雄激素受体抑制剂的获益-风险特征。尽管下一代影像技术引发管理标准争议,已发表的共识声明仍认为传统影像无转移即可指导治疗决策。三种药物的关键临床试验显示无转移生存期延长及近期报告的总生存期阳性结果,支持早期使用以延缓转移和延长生存。

要点

  • nmCRPC患者常无症状但年龄偏大且合并症多,需权衡治疗获益与风险。
  • 传统影像无转移仍是现有共识指导治疗决策的标准。
  • 三种第二代雄激素受体抑制剂均显示无转移生存期延长及总生存期阳性结果。

核心结论

  • 三种第二代雄激素受体抑制剂(阿帕他胺、恩扎卢胺、达罗他胺)的延长无转移生存期及近期报告的总生存期阳性结果为nmCRPC早期使用这些药物以延缓转移和延长生存提供了进一步证据。

研究设计与样本

  • 本文为综述,讨论nmCRPC早期治疗的理由及影响治疗决策的因素,聚焦口服第二代雄激素受体抑制剂并基于其关键临床试验数据讨论获益-风险特征。

主要发现

  • nmCRPC患者会进展为转移性疾病并面临癌症相关症状和死亡风险。
  • nmCRPC患者通常无症状但年龄较大且合并需要长期伴随用药的慢性疾病。
  • 下一代影像技术可检测传统影像无法发现的寡转移病变,引发了关于管理标准的讨论。
  • 已发表的共识声明仍认为传统影像无转移足以指导治疗决策。
  • 三种第二代雄激素受体抑制剂均显示无转移生存期延长及近期报告的总生存期阳性结果。

关键数值与推荐

  • nmCRPC定义为持续雄激素剥夺治疗或睾丸切除术后睾酮达去势水平下前列腺特异性抗原浓度升高,且传统影像未检出转移。
  • 已发表的共识声明认为传统影像无转移足以指导治疗决策。

临床怎么用

  • 对nmCRPC患者可考虑早期使用第二代雄激素受体抑制剂以延缓转移和延长生存。
  • 选择阿帕他胺、恩扎卢胺或达罗他胺时需平衡临床获益与潜在不良事件对生活质量、体能和认知功能的影响。
  • 治疗决策需考虑患者年龄、慢性合并症及长期伴随用药情况。

局限性

  • 下一代影像技术可检测传统影像无法发现的寡转移病变,对基于传统影像的管理标准提出挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nonmetastatic castration-resistant prostate cancer (nmCRPC) is defined as a rising prostate-specific antigen concentration, despite castrate levels of testosterone with ongoing androgen-deprivation therapy or orchiectomy, and no detectable metastases by conventional imaging. Patients with nmCRPC progress to metastatic disease and are at risk of developing cancer-related symptoms and morbidity, eventually dying of their disease. While patients with nmCRPC are generally asymptomatic from their disease, they are often older and have chronic comorbidities that require long-term concomitant medication. Therefore, careful consideration of the benefit-risk profile of potential treatments is required. METHODS: In this review, we will discuss the rationale for early treatment of patients with nmCRPC to delay metastatic progression and prolong survival, as well as the factors influencing this treatment decision. We will focus on oral pharmacotherapy with the second-generation androgen receptor inhibitors, apalutamide, enzalutamide, and darolutamide, and the importance of balancing the clinical benefit they offer with potential adverse events and the consequential impact on quality of life, physical capacity, and cognitive function. RESULTS AND CONCLUSIONS: While the definition of nmCRPC is well established, the advent of next-generation imaging techniques capable of detecting hitherto undetectable oligometastatic disease in patients with nmCRPC has fostered debate on the criteria that inform the management of these patients. However, despite these developments, published consensus statements have maintained that the absence of metastases on conventional imaging suffices to guide such therapeutic decisions. In addition, the prolonged metastasis-free survival and recently reported positive overall survival outcomes of the three second-generation androgen receptor inhibitors have provided further evidence for the early use of these agents in patients with nmCRPC in order to delay metastases and prolong survival. Here, we discuss the benefit-risk profiles of apalutamide, enzalutamide, and darolutamide based on the data available from their pivotal clinical trials in patients with nmCRPC.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Saad F, Bögemann M, Suzuki K, et al. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors. Prostate Cancer Prostatic Dis. 2021. PMID: 33558665. doi:10.1038/s41391-020-00310-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。